These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24318884)

  • 21. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
    Macejak DG; Jensen KL; Jamison SF; Domenico K; Roberts EC; Chaudhary N; von Carlowitz I; Bellon L; Tong MJ; Conrad A; Pavco PA; Blatt LM
    Hepatology; 2000 Mar; 31(3):769-76. PubMed ID: 10706571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trans-splicing ribozymes for targeted gene delivery.
    Köhler U; Ayre BG; Goodman HM; Haseloff J
    J Mol Biol; 1999 Feb; 285(5):1935-50. PubMed ID: 9925776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
    Chang LJ; Liu X; He J
    Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the retroviral ribonuclease H by rational drug design.
    Moelling K
    AIDS; 2012 Oct; 26(16):1983-93. PubMed ID: 22555171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catalytic strategies of the hepatitis delta virus ribozymes.
    Shih IH; Been MD
    Annu Rev Biochem; 2002; 71():887-917. PubMed ID: 12045114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of ribozyme gene therapy for the inhibition of HIV replication and its pathogenic sequelae.
    Rigden JE; Ely JA; Macpherson JL; Gerlach WL; Sun LQ; Symonds GP
    Curr Issues Mol Biol; 2000 Apr; 2(2):61-9. PubMed ID: 11471565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of HIV-1 replication and dimerization interference by dual inhibitory RNAs.
    Sánchez-Luque FJ; Reyes-Darias JA; Puerta-Fernández E; Berzal-Herranz A
    Molecules; 2010 Jul; 15(7):4757-72. PubMed ID: 20657391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication.
    Riguet E; Tripathi S; Chaubey B; Désiré J; Pandey VN; Décout JL
    J Med Chem; 2004 Sep; 47(20):4806-9. PubMed ID: 15369382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 30. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes.
    Düzgünes N; Simões S; Slepushkin V; Pretzer E; Rossi JJ; De Clercq E; Antao VP; Collins ML; de Lima MC
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):515-23. PubMed ID: 11563068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
    Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
    Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retroviral delivery and anti-HIV testing of hammerhead ribozymes.
    Cagnon L; Rossi J
    Methods Mol Biol; 1997; 74():451-7. PubMed ID: 9204460
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.
    Radi M; Falchi F; Garbelli A; Samuele A; Bernardo V; Paolucci S; Baldanti F; Schenone S; Manetti F; Maga G; Botta M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2094-8. PubMed ID: 22300661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd.
    de Feyter R; Li P
    Curr Opin Mol Ther; 2000 Jun; 2(3):332-5. PubMed ID: 11249628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid.
    Ohkawa J; Yuyama N; Taira K
    Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The sCYMV1 hairpin ribozyme: targeting rules and cleavage of heterologous RNA.
    Lian Y; De Young MB; Siwkowski A; Hampel A; Rappaport J
    Gene Ther; 1999 Jun; 6(6):1114-9. PubMed ID: 10455414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA as a target for developing antivirals.
    McKnight KL; Heinz BA
    Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.